POS1090 IMPLEMENTATION OF QUALITY STANDARDS FOR HEALTH CARE OF PATIENTS WITH RHEUMATOID ARTHRITIS: FIRST RESULTS FROM THE NATIONAL DATABASE OF THE GERMAN COLLABORATIVE ARTHRITIS CENTRES

Background Despite the establishment of national and international recommendations for management patients with rheumatoid arthritis (RA), remediable deficits in quality care (QoC) still exist. On behalf German Society Rheumatology, participation patient organization Deutsche Rheuma-Liga, eight Quality standards (QS) have been developed to improve QoC Germany. The QS can be used determine quantitative gaps respect time diagnosis, use glucocorticoids, rates remission impairments physical function [1]. Objectives To quantify based on five RA whom data from National Database Collaborative Arthritis Centres (NDB) exists. Methods In 2020, 4863 12 Rheumatology centres were followed NDB. Five reviewed: (QS1) How often was diagnosed within 8 weeks symptom onset? (QS2) many are remission? (QS3) glucocorticoid-free (QS4) who not had their medication adjusted? (QS5) received physiotherapy, functional training, and/or rehabilitation? Remission investigated both by DAS28 CDAI cut-offs. Impairments assessed FFbH (≤70% full function). Switches, additions, or dose increases disease-modifying antirheumatic drug (DMARD) considered adjustment medication. Individual components reported reasons achieving remission. Results Fulfillment (Figure 1) (Table 1). 76 first contact rheumatologist 30 seen a (39%). Of 61 available diagnosis date, 25 (41%) weeks. 1523 3410 (45%) 933 4023 (23%). 1155 1520 789 930 (76%/85%). 373 1676 (22%). Patients without therapy fewer clinical signs inflammatory activity (SJC 1.3 vs. 2.6, TJC 2.6 3.7, ESR 25.7 27.4, Physician global 1.8 2.8, Patient disease 4.1 4.8) compared 68 149 high (DAS28>5.1) (46%). 377 772 information physiotherapy (49%), 32 767 training (4%) 117 1175 rehabilitation (10%). Table 1. characteristics, n=4863 Female sex (%) 74 Age, mean years 63 Disease duration, mean, 14 ACPA RF positive 72 DAS28, (n=3,410) 2.9 CDAI, (n=4,023) 7.7 TJC, 1.6 SJC, 1.0 ESR, mm/h 19.1 activity, 3.5 1.5 Functional assessment (FFbH 0-100), (n=4526) 75.4 cs/bDMARDs 70/ 29 Glucocorticoids 35 First visit n Duration symptoms, mean/median, months 20.2/4.0 Rheumatologist weeks, (39%) Diagnosis (n=61 date) Figure Conclusion With new QS, measured standardized form. While some results reflect care, other QSs point opportunities improvement. implementation enables comparative evaluation at facility level general rheumatology health outcome. This will help optimize Reference [1]PMID 34652486 Acknowledgements We thank all participating rheumatologists valuable contributions. NDB is supported Association Regional Cooperative Centres, joint contributions Rheumatological Training Academy DRFZ following members Working Group Corporate Members Rheumatology: AbbVie, AstraZeneca, BMS, GALAPAGOS, GSK, Lilly, Medac, MSD, Pfizer, Sanofi-Aventis UCB. Disclosure Interests Katinka Albrecht: None declared, Katja Thiele: Martin Aringer: Johanna Callhoff Speakers bureau: Janssen-Cilag GmbH, Kirsten Karberg: Klaus Krueger: Jürgen Lakomek: Hanns-Martin Lorenz: Rudwaleit Abbvie, Boehringer, Galapagos, Janssen, Novartis, UCB, Rotraud Schmale-Grede: Matthias Schneider: Susanna Spaethling-Mestekemper: Christof Specker: Silke Zinke: Braun: Uta Kiltz: declared.